Laurus labs witnessed significant institutional trading activity with a substantial block trade executed on the National Stock Exchange (NSE). The transaction represents one of the notable trading activities in the pharmaceutical sector.

Block Trade Details

The block trade involved substantial market activity with the following parameters:

Market Significance

Block trades typically represent large institutional transactions that are executed outside the regular market to avoid significant price impact. Such transactions often involve mutual funds, insurance companies, foreign institutional investors, or other large market participants looking to buy or sell substantial quantities of shares.

The execution price of Rs. 1064.70 per share for this transaction indicates the level at which institutional investors were willing to transact in Laurus Labs stock. The substantial volume of 563,347 shares demonstrates significant institutional interest in the pharmaceutical company's equity.

Laurus Labs has received approval from the National Company Law Tribunal (NCLT), Amaravati Special Branch, for its composite scheme of arrangement involving the restructuring of its wholly-owned subsidiaries. The order was pronounced on February 24, 2026, marking a significant step in the company's corporate reorganization strategy.

NCLT Order Details

The tribunal approved the company's application for a composite scheme involving three entities: Laurus Synthesis Private Limited (LSPL) as the transferor company, Sriam Labs Private Limited as the resulting company, and Laurus Labs Limited as the transferee company. The scheme encompasses two key components: demerger of the Identified Business Undertaking (Unit-1 of LSPL) to merge with Sriam Labs, and amalgamation of the remaining LSPL business undertakings with Laurus Labs.

Meeting Dispensations and Requirements

The NCLT dispensed with several meetings based on consent affidavits obtained from stakeholders. The tribunal waived meetings of equity shareholders and secured creditors for both subsidiary companies, as well as all meetings for the transferee company (Laurus Labs). This decision was supported by the fact that both subsidiaries are wholly-owned by Laurus Labs, and the scheme does not affect the rights of the parent company's stakeholders.

However, the tribunal directed convening of unsecured creditor meetings for both subsidiaries:

Financial Structure and Rationale

The composite scheme aims to achieve consolidation, greater integration, and financial strength while maximizing shareholder value. The restructuring will enable economies in business operations, optimal resource utilization, and enhanced administrative efficiencies.

Share Capital Details:

Under the scheme, the Resulting Company will issue 27 equity shares for every one equity share held by LSPL shareholders. All equity shares held by Laurus Labs in LSPL will be cancelled without any consideration, as per the amalgamation provisions.

Regulatory Compliance and Next Steps

The companies have obtained necessary certifications from statutory auditors confirming compliance with accounting standards, along with valuation reports and fairness opinions from registered valuers and independent merchant bankers. The scheme falls within exemptions under competition law as it involves entities of the same group without change in control.

The tribunal directed the companies to serve notices on regulatory authorities including the Regional Director, Registrar of Companies, Income Tax authorities, SEBI, stock exchanges, and drug control administrators. These authorities have 30 days to make representations, failing which they will be deemed to have no objections to the proposed scheme.